Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C6H11O7.Zn.3H2O |
Molecular Weight | 509.75 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[Zn++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O
InChI
InChIKey=ZPQPBMFYUZNVPE-BMDZSJGYSA-L
InChI=1S/2C6H12O7.3H2O.Zn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;/h2*2-5,7-11H,1H2,(H,12,13);3*1H2;/q;;;;;+2/p-2/t2*2-,3-,4+,5-;;;;/m11..../s1
Molecular Formula | Zn |
Molecular Weight | 65.409 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H12O7 |
Molecular Weight | 196.1553 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfCurator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Sources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf
Curator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
There is no available information related any biological or pharmacutical application of AMMONIUM PENTACHLOROZINCATE
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25374537 | https://www.ncbi.nlm.nih.gov/pubmed/15639165https://www.ncbi.nlm.nih.gov/pubmed/2307275https://www.ncbi.nlm.nih.gov/pubmed/10721938http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Curator's Comment: Glucarpidase hydrolyzes the methotrexate in the blood but cannot cross the blood-brain barrier, nor can it break down intracellular methotrexate.
Originator
Sources: http://sciencing.com/uses-zinc-carbonate-7889200.htmlhttps://www.webelements.com/zinc/history.htmlhttp://www.drugdevelopment-technology.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612426 |
|||
Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083 |
|||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783 |
|||
Target ID: CHEMBL2364710 |
|||
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194 |
|||
Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | CORTROPHIN-ZINC Approved UseTreatment of ulcerative colitis and other colonic disorders. Launch Date-4.55328006E11 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Secondary | VORAXAZE Approved UseIndicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date1.32675836E12 |
|||
Primary | VUSION Approved UseINDICATIONS AND USAGE
VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when
complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or
budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal
culture for Candida albicans is not adequate evidence of candidal infection since colonization
with C. albicans can result in a positive culture. The presence of candidal infection should be
established by microscopic evaluation prior to initiating treatment.
VUSION Ointment should be used as part of a treatment regimen that includes measures
directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and
frequent diaper changes. Launch Date1.140048E12 |
|||
Primary | ZINC OXIDE Approved UseUnknown |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
PubMed
Title | Date | PubMed |
---|---|---|
In vitro activity of zinc salts against human rhinoviruses. | 1987 Apr |
|
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. | 1991 Sep 10 |
|
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds. | 1994 Dec |
|
Thujaplicin-copper chelates inhibit replication of human influenza viruses. | 1998 Aug |
|
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study. | 1999 Spring |
|
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. | 2000 Sep |
|
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age. | 2004 |
|
Impact of the mother's zinc deficiency on the woman's and newborn's health status. | 2005 |
|
Erythrocyte zinc content in critically ill patients. | 2005 |
|
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections]. | 2005 |
|
Zinc in attention-deficit/hyperactivity disorder. | 2005 Aug |
|
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. | 2005 Aug |
|
[Reduced thymulin production during occupational exposure to lead]. | 2005 Jan-Mar |
|
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet. | 2005 Nov-Dec |
|
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder. | 2005 Sep 1 |
|
Effects of zinc supplementation in patients with type 1 diabetes. | 2005 Summer |
|
Characterization and inhibition of SARS-coronavirus main protease. | 2006 |
|
Copper and zinc concentrations in serum of healthy Greek adults. | 2006 Apr 15 |
|
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs. | 2006 Dec |
|
The effect of Ramadan on maternal nutrition and composition of breast milk. | 2006 Jun |
|
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality. | 2006 May |
|
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. | 2007 May |
|
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing. | 2010 Dec |
|
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles. | 2010 Feb |
|
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells. | 2010 Jan 12 |
|
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010 Oct |
|
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways. | 2011 Dec |
|
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles. | 2011 Mar 21 |
|
Zinc induces chemokine and inflammatory cytokine release from human promonocytes. | 2011 Nov 30 |
|
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. | 2012 Apr |
|
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity. | 2012 Feb |
|
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells. | 2012 Mar |
|
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide. | 2012 Mar |
|
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation. | 2013 Dec |
|
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils. | 2013 Jul 31 |
|
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells. | 2013 Mar |
|
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling. | 2014 Apr |
|
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles. | 2014 Jan |
|
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation. | 2014 Jul 1 |
|
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line. | 2014 Mar 3 |
|
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition. | 2014 May 16 |
|
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice. | 2014 Nov 4 |
|
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design. | 2015 |
|
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity. | 2015 Apr 2 |
|
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode. | 2016 Mar 5 |
|
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process. | 2016 Oct |
|
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents. | 2016 Oct 1 |
|
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers. | 2016 Sep |
|
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations. | 2016 Sep 21 |
|
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass. | 2017 May 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10978858
Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and
represented 40% of the recommended daily allowance of a male
adult human. This dose was administered in water solution at a
final volume of 1 mL per rat.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1320875
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:52:55 UTC 2023
by
admin
on
Wed Jul 05 23:52:55 UTC 2023
|
Record UNII |
F2F0XU34WQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00154138
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | |||
|
1440975
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | RxNorm | ||
|
DBSALT002891
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | |||
|
100000127139
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | |||
|
SUB32332
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | |||
|
12389-19-4
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | |||
|
F2F0XU34WQ
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | |||
|
F2F0XU34WQ
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY | |||
|
71586951
Created by
admin on Wed Jul 05 23:52:55 UTC 2023 , Edited by admin on Wed Jul 05 23:52:55 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |